[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
It is important for achieving complete remission of acute myelogenous leukemia to manage anemia and bone marrow hypoplasia, which cause serious complications. Anemia and bone marrow hypoplasia are mainly treated by supportive therapies consisting of granulocyte-colony stimulating factor, red blood cell transfusion and platelet transfusion, which are given according to recommendations of guidelines. In addition to these supportive therapies, new drugs such as DNA demethylating agents are developed for myelodysplastic syndrome (MDS). These drugs are expected to improve a cytopenia, and reduce the frequency of transfusions.
Department of Hematology and Rheumatology, Tohoku University School of Medicine.
Hisayuki
H
Yokoyama
Hideo
H
Harigae
D000740:Anemia / Q000209:etiology* / Q000628:therapy*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology*; D001855:Bone Marrow Diseases / Q000209:etiology* / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D000077209:Decitabine; D015195:Drug Design; D017707:Erythrocyte Transfusion; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications* / Q000628:therapy*; D017713:Platelet Transfusion; D017410:Practice Guidelines as Topic
D000964:Antimetabolites, Antineoplastic; D016179:Granulocyte Colony-Stimulating Factor; D000077209:Decitabine; D001374:Azacitidine